Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 336

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Open access
Wolf, Denise M., Yau, Christina, Wulfkuhle, Julia, Brown-Swigart, Lamorna, Gallagher, Rosa I., Lee, Pei Rong Evelyn, Zhu, Zelos, Magbanua, Mark J., Sayaman, Rosalyn, O’Grady, Nicholas, Basu, Amrita, Delson, Amy, Coppé, Jean Philippe, Lu, Ruixiao, Braun, Jerome, Asare, Smita M., Sit, Laura, Matthews, Jeffrey B., Perlmutter, Jane, Hylton, Nola, Liu, Minetta C., Pohlmann, Paula, Symmans, W. Fraser, Rugo, Hope S., Isaacs, Claudine, DeMichele, Angela M., Yee, Douglas, Berry, Donald A., Pusztai, Lajos, Petricoin, Emanuel F., Hirst, Gillian L., Esserman, Laura J., van 't Veer, Laura J.·2022·Cancer Cell

Abstract

Using pre-treatment gene expression, protein/phosphoprotein, and clinical data from the I-SPY2 neoadjuvant platform trial (NCT01042379), we create alternative breast cancer subtypes incorporating tumor biology beyond clinical hormone receptor (HR) and human epidermal growth factor receptor-2 (HER2) status to better predict drug responses. We assess the predictive performance of mechanism-of-action biomarkers from ∼990 patients treated with 10 regimens targeting diverse biology. We explore >11 subtyping schemas and identify treatment-subtype pairs maximizing the pathologic complete response (pCR) rate over the population. The best performing schemas incorporate Immune, DNA repair, and HER2/Luminal phenotypes. Subsequent treatment allocation increases the overall pCR rate to 63% from 51% using HR/HER2-based treatment selection. pCR gains from reclassification and improved patient selection are highest in HR + subsets (>15%). As new treatments are introduced, the subtyping schema determines the minimum response needed to show efficacy. This data platform provides an unprecedented resource and supports the usage of response-based subtypes to guide future treatment prioritization.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2022.05.005

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 336

Metadata

Authors
Wolf, D. M., Yau, C., Wulfkuhle, J., Brown-Swigart, L., Gallagher, R. I., Lee, P. R. E., Zhu, Z., Magbanua, M. J., Sayaman, R., O’Grady, N., Basu, A., Delson, A., Coppé, J. P., Lu, R., Braun, J., Asare, S. M., Sit, L., Matthews, J. B., Perlmutter, J., Hylton, N., Liu, M. C., Pohlmann, P., Symmans, W. F., Rugo, H. S., Isaacs, C., DeMichele, A. M., Yee, D., Berry, D. A., Pusztai, L., Petricoin, E. F., Hirst, G. L., Esserman, L. J., & van 't Veer, L. J.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2022-06
Volume
40
Issue
6
Pages
609-623.e6
ISSN
1535-6108 (ISSN-L)
OpenAlex
W4281559326
Cited by
336
References
43
FWCI
22.68
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. https://app.cochat.ai/papers/10.1016/j.ccell.2022.05.005
The paper
Wolf, D. M., Yau, C., Wulfkuhle, J., Brown-Swigart, L., Gallagher, R. I., Lee, P. R. E., Zhu, Z., Magbanua, M. J., Sayaman, R., O’Grady, N., Basu, A., Delson, A., Coppé, J. P., Lu, R., Braun, J., Asare, S. M., Sit, L., Matthews, J. B., Perlmutter, J., . . . van 't Veer, L. J. (2022). Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. https://doi.org/10.1016/j.ccell.2022.05.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.